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Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite a
multimodal therapy consisting of resection followed by fractionated radiotherapy (RT) combined with the
chemotherapeutic agent (CT) temozolomide (TMZ), its recurrence is almost inevitable. Since the immune system is
capable of eliminating small tumor masses, a therapy should also aim to stimulate anti-tumor immune responses
by induction of immunogenic cell death forms. The histone deacetylase inhibitor valproic acid (VPA) might
foster this.
Methods: Reflecting therapy standards, we applied in our in vitro model fractionated RT with a single dose of 2Gy
and clinically relevant concentrations of CT. Not only the impact of RT and/or CT with TMZ and/or VPA on the
clonogenic potential and cell cycle of the glioblastoma cell lines T98G, U251MG, and U87MG was analyzed, but also
the resulting cell death forms and release of danger signals such as heat-shock protein70 (Hsp70) and high-mobility
group protein B1 (HMGB1).
Results: The clonogenic assays revealed that T98G and U251MG, having mutated tumor suppressor protein p53,
are more resistant to RT and CT than U87MG with wild type (WT) p53. In all glioblastoma cells lines, fractionated RT
induced a G2 cell cycle arrest, but only in the case of U87MG, TMZ and/or VPA alone resulted in this cell cycle
block. Further, fractionated RT significantly increased the number of apoptotic and necrotic tumor cells in all three
cell lines. However, only in U87MG, the treatment with TMZ and/or VPA alone, or in combination with fractionated
RT, induced significantly more cell death compared to untreated or irradiated controls. While necrotic glioblastoma
cells were present after VPA, TMZ especially led to significantly increased amounts of U87MG cells in the
radiosensitive G2 cell cycle phase. While CT did not impact on the release of Hsp70, fractionated RT resulted in
significantly increased extracellular concentrations of Hsp70 in p53 mutated and WT glioblastoma cells.
Conclusions: Our results indicate that fractionated RT is the main stimulus for induction of glioblastoma cell death
forms with immunogenic potential. The generated tumor cell microenvironment might be beneficial to include
immune therapies for GBM in the future.
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Glioblastoma multiforme (GBM) is the most common
and malignant primary brain tumor in adults. It is charac-
terized by its aggressive, diffuse infiltrative and invasive
growth. The extensive cellular and molecular heterogen-
eity of GBM may contribute to poor prognosis of the pa-
tients [1]. Because of the infiltrative growth of the tumor a
complete resection is difficult and radiation (RT) mostly
combined with chemotherapy (CT) follow as adjuvant
treatments. A conventional RT scheme consists of a total
dose of 60Gy, given at 5 consecutive days weekly in 2Gy
fractions over 6 weeks. The most widely used chemothera-
peutics in GBM treatment are alkylating agents, including
the well tolerated imidazoletetrazinone derivative temozo-
lomide (TMZ), since the lipophilic properties allow to pass
the blood brain barrier. Stupp et al. reported about an im-
proved median survival from 12.1 to 14.6 months and an
increased 5-years survival from 1.9% to 9.8% of patients
with GBM treated with concomitant and adjuvant TMZ
and RT compared to RT alone [2].
Levels of oral administered TMZ in the brain or the
cerebrospinal fluid reach about 30-40% [3] of the plasma
concentration, which ranges between 27 μM and 50 μM
[4]. Its cytotoxicity is due to the methylation of the O6
position of guanine. This causes mispairing with thymine
during the next replication cycle [5]. However, the pres-
ence of the DNA repair protein O6-methylguanine methyl-
transferase (MGMT) in a large number of gliomas confers
to resistance of alkylating agents [6]. Therefore the promo-
tor methylation of the MGMT gene, observed for GBM
and various other tumor types, results in an improved
outcome for patients, through decreased expression of
the dealkylating protein [7]. As already demonstrated by
in vitro experiments, TMZ is capable of inducing cell
cycle arrest in the G2/M phase [8], senescence [9],
apoptosis [10], or autophagy [11] in glioma cells. Data
about the release of danger signals and the loss of the
tumor cell membrane integrity, characteristic for pri-
mary and secondary necrotic cells, are still lacking.
Epileptic seizures are common in 30 to 50% of GBM
patients [12]. Patients receiving valproic acid (VPA) as
anticonvulsant during TMZ based radiotherapy have a
better outcome than patients treated with other antiepi-
leptic drugs (AED) or not receiving any AED [13]. VPA
can be administered orally and also crosses the blood-
brain barrier [14]. Levels in the brain reach about 7 to
28% of the serum/plasma concentration, which ranges
between 20-100 μg/ml in epilepsy patients [15]. Fur-
thermore, VPA is an effective histone deacetylase
(HDAC) inhibitor [16]. It induces growth arrest, apop-
tosis, senescence, and autophagy in medullablastoma
and glioma cells [17,18]. A sensitization by VPA of hu-
man glioma cells to TMZ and irradiation was just re-
ported recently [19].The tumor suppressor gene p53 plays a major role in the
regulation of cellular stress responses. In non-malignant
cells the p53 protein has a short half-life time and is
expressed at low levels. However, its protein level increases
after exposure to stress stimuli like ionizing radiation, gen-
otoxic DNA-damaging agents or hypoxia, thereby modu-
lating cell cycle, DNA repair, apoptosis, senescence, cellular
differentiation, metabolism, angiogenesis and immune re-
sponse. Nevertheless, the function of p53 is often altered
or impaired due to mutations after neoplastic transform-
ation. Mutations in p53 have been seen in 25-30% of pri-
mary GBM [20,21]. The incidence of p53 mutations in
glioma cell lines is similar to the primary tumor [22]. Sev-
eral established human GBM cell lines with wild type (WT,
e.g. in U87MG) or mutant p53 (e.g. in T98G, U251MG,
U138MG, A-172) exist for studying the impact of p53 in
cancer treatment [23].
The contribution of the immune system in eliminating
small tumor masses, recurrent tumors or metastases has
become increasingly evident [24,25]. Chemotherapeutic
agents and γ-irradiation induce DNA damage, which leads
to cell cycle arrest and proliferation stop. Irreparable dam-
ages result in the induction of senescence or distinct
forms of cell death [26,27]. The two main cell death forms
are apoptosis and necrosis. In contrast to necrotic cells,
apoptotic cells are usually non-inflammatory or even anti-
inflammatory, because of their maintenance of the plasma
membrane integrity and swift clearance by macrophages.
However, some chemotherapeutic agents, like anthracy-
clines and oxaliplatin, as well as ionizing irradiation are
capable of inducing immunogenic forms of apoptotic cell
death [28]. Because of the loss of membrane integrity, nec-
rotic cell death leads, besides a supply of tumor-associated
antigens (TAA), to the release of damage-associated mo-
lecular pattern molecules (DAMP), which trigger inflam-
mation and immune activation [29,30]. Formerly only
known as non-programmed form of cell death, regulated
necrosis has become evident during the last years. The so
called necroptosis is negatively regulated by caspase-8 and
is dependent on the kinase activity of RIPK3 and RIPK1
[31]. The latter is inhibitable by necrostatin-1, while
caspase-dependent apoptosis is inhibitable by the pan-
caspase inhibitor zVAD-fmk [32,33]. Secondary necrotic
cells result from apoptotic cells that were not properly
cleared and have lost their membrane integrity at any time
point during apoptosis execution [34,35]. Primary non-
programmed necrosis is characterized by early plasma
membrane rupture and dilatation of cytoplasmic organ-
elles [36]. The early plasma membrane rupture can be in-
duced by mechanical stress or take place in very early
phases after apoptosis induction when no DNA degrad-
ation has already taken place [37]. We here define primary
necrotic cells as cells that have lost their membrane integ-
rity but still have full DNA content. Secondary necrotic
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degraded their DNA and lost the membrane integrity. RT-
and CT-induced glioblastoma cell death was inhibitable
by zVAD-fmk, but not by necrostatin-1 (not shown). This
suggests that mainly secondary necrosis and no RIPK1-
dependent necroptosis was induced in the examined glio-
blastoma cell lines.
Released danger signals by necrotic cells in general,
such as the heat shock protein 70 (Hsp70) and the
DNA-binding protein high-mobility group B1 (HMGB1)
activate dendritic cells (DC) and foster the efficient pro-
cessing and (cross) presentation of antigens, respectively.
DC are professional antigen presenting cells (APC) and
crucial for the priming of tumor-specific naïve T cells
[38]. For the induction of an efficient antitumor immune
response the activation of both cytotoxic CD8+ T cells
and CD4+ T helper cells is required [39]. Intracellular
antigens are usually presented on MHC class I to CD8+
T cells and extracellular antigens such as TAA are
presented on MHC class II to CD4 +T cells. However,
HMGB1 and Hsp70 enable DC to also cross-present TAA
in a MHC class I dependent manner [40]. In that way, not
only T helper cells, but also cytotoxic T cells are primed.
Little is known about tumor cell death forms that are in-
duced by the combination of RT and CT in GBM. Espe-
cially the knowledge about combined treatments which
could change the immunosuppressive tumor microenvir-
onment to an immune stimulating one is rare. Further,
most of the in vitro studies that determine the response of
tumor cells to chemotherapeutics alone or in combination
with RT use much higher doses of CT and RT compared
to clinical routine applications. Preclinical models repro-
ducing clinical conditions are needed for radiobiological
studies [41]. Commonly, the clonogenic (or colony form-
ing) assay is used as read out to determine the reproductive
viability of cells after single and multimodal treatments.
The surviving fraction is expressed by the linear-quadratic
model which predicts the sensitivity and repair capacity of
cells to radiation and/or CT. This dose response relation-
ship model is still the biological basis for most of the RT
schemes in the clinics. Nevertheless, is has several draw-
backs, including that the cells are seeded in different con-
centrations, depending on the treatment, the low plating
efficiency, the disregarded cell-to-cell communication,
and clump artifacts. Further, the colony forming assay
does not allow any assumption about cell death induc-
tion and forms of tumor cell death including their im-
munogenicity [42,43].
Because of the above mentioned, our purpose was to
examine cell death forms of p53 WT and p53 mutated
glioblastoma cell lines with an in vitro system that re-
sembles closer to clinical protocols in GBM treatment.
We here focused on apoptosis and necrosis of the three
human glioblastoma cell lines U87MG (p53 WT), U251MG(p53 mutated), and T98G (p53 mutated) induced by
conventional fractionated RT (5x2Gy, weekly dose) in
combination with clinically achievable levels of TMZ.
We further examined whether VPA influences/increases
the radiosensitivity of glioma cells. To get hints about
the immunogenic potential of glioblastoma cells, besides
the analysis of apoptosis and necrosis by AnnexinA5-
FITC/PI staining, the release of the immune activating
danger signals HMGB1 and HSP70 was assessed.
Methods
Cell culture and reagents
The human glioblastoma tumor cell lines U87MG and
T98G were obtained from the American Type Culture
Collection (ATCC; Manassas, USA), and U251MG from
Cell Line Service (CLS; Eppelheim, Germany). The cell
lines were tested to be free of mycoplasma contamin-
ation before performing the experiments. Cells were
maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM; PAN-Biotech GmbH, Aidenbach, Germany)
supplemented with 10% fetal bovine serum (FBS; Bio-
chrom AG, Berlin, Germany), 1% sodium pyruvate, 2 mM
glutamine, 100U/ml penicillin and 100 μg/ml strepto-
mycin (termed D10 medium; Invitrogen, Darmstadt,
Germany). Cells were grown in cell culture flasks (Cellstar;
Greiner BioOne, Nürtlingen, Germany) at 37°C in humidi-
fied air with 5% CO2. TMZ and VPA were purchased
from Sigma-Aldrich (Munich, Germany). TMZ was dis-
solved at a stock concentration of 100 mM in dimethylsulf-
oxide (DMSO) and stored at -20°C. Chemotherapeutics
were diluted in D10 immediately before treatment of cells.
Treatment with chemotherapeutic agents and X-ray
The glioblastoma cells were seeded at a density of 2.5 ×
105 cells in 75 cm2 flasks. The chemotherapeutics were
added 24 h (0.5 mM VPA) or 40 h (20 μM TMZ) later.
Two hours after TMZ treatment, cells were irradiated
with 2Gy (representing a daily dose in GBM therapy). Ir-
radiation was repeated on four consecutive days to
achieve a clinically relevant total weekly dose of 10Gy.
Forty-eight hours after the last radiation, supernatants
for ELISA (enzyme-linked immunosorbent assay) ana-
lyses were collected, and cells were harvested for cell
death detection and cell cycle analysis by flow cytometry.
Irradiation was performed with an X-ray generator
(120 kV, 22.7 mA, variable time; GE Inspection Tech-
nologies, Hürth, Germany).
Clonogenic assay
The effect of TMZ and VPA or a combination of both
on the radiosensitivity of the three glioblastoma cell lines
was assessed with clonogenic assays. Cells were plated in
triplicates in 60-mm dishes (Nunc Thermo Fisher, Waltham,
USA) at concentrations estimated to yield 40-150
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(0.5 mM VPA) or 40 h (20 μM TMZ) after seeding.
Two hours after TMZ treatment, cells were irradiated
with 1, 2, 4, 6, 8 or 10Gy. After incubation for ~2 weeks,
cells were fixed with methylene blue (Sigma-Aldrich,
Munich, Germany) for 30 min. Colonies with >50 cells
were scored.
Cell death detection
Induction of cell death in glioblastoma cells and cell death
forms by the respective treatments were examined using
AnnexinA5 (AnxA5)-FITC/Propidium Iodide (PI) stain-
ing. The cell suspensions (1 × 106 cells/ml) were incubated
for 30 min at 4°C in the dark with 0.5 μg/ml AnxA5-FITC
(Geneart, Regensburg, Germany; FluoroTaq FITC conju-
gation Kit, Sigma-Aldrich, Munich, Germany) and 1 μg/
ml PI (Sigma-Aldrich, Munich, Germany) in Ringer’s So-
lution (Baxter S.A., Lessines, B). Samples were analyzed by
flow cytometry (EPICS XL MCL™, Beckman Coulter, Brea,
USA) and its associated Kaluza 1.1 Software®. A minimum
of 10.000 events/sample were acquired. Viable cells show
neither binding of AnxA5 nor staining with PI. Early
apoptotic cells are positive for AnxA5 binding and PI
negative, whereas late apoptotic cells (referred as second-
ary necrotic ones, AnxA5+/PI+) and necrotic cells (re-
ferred as primary necrotic ones, AnxA5+/PI++) were
positive for both, AnnexinA5 and PI binding. Inhibitors
for necroptosis and apoptosis were used in selected ex-
periments to determine whether the detected necrosis
by AnxA5-FITC/PI staining is necroptosis or second-
ary necrosis. The necroptosis inhibitor necrostatin-1
(nec-1; Sigma-Aldrich, Munich, Germany) was used in
the concentration of 10 μM and the pan-caspase in-
hibitor carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl]-
fluoromethyl-ketone (zVAD-fmk Bachem, Weil am Rhein,
Germany) in the concentration of 50 μM.
Cell cycle analysis
Cell cycle phases and the cells with sub-G1 DNA content
were analyzed by PI staining in the presence of detergent
followed by analysis with flow-cytometry as described by
Riccardi and Nicoletti [44]. In brief, cells (5 × 105) were
fixed at least for 20 min in 70% ethanol at -20°C. After
permeabilization of cells with TritonX-100 containing so-
lution, cells were incubated for 30 min with 200 μg/ml
RNase A (Roche, Mannheim, Germany) and 5 μg/ml PI at
room temperature. DNA content was determined with
Kaluza 1.1 Software® (Beckman Coulter, Krefeld, Germany)
after excluding doublets and clumps by gating on the FL3
versus FL3(AUX).
ELISA for Hsp70 and HMGB1 in cell culture supernatants
Cell culture supernatants were centrifuged to remove
remaining cells and stored at -80°C until the determinationof extracellular HMGB1 or Hsp70 concentrations by ELISA
technique. The Hsp70 ELISA kit was purchased by R&D
Systems (DuoSet®, Wiesbaden-Nordenstadt, Germany) and
that of HMGB1 by Shino-Test Corporation (Kanagawa,
Japan). ELISA were performed according to the manufac-
turer’s instructions.
Statistical analysis
Data were expressed as the mean ± standard deviation
(SD) and analyzed for statistical significance using Stu-
dents t-test (t-tailed) or non-parametric Mann-Whitney
U-test (GraphPad Prism®, La Jolla, USA). A p value <0.05
was considered to be significant.
Results
The extent of radiosensitization by the chemotherapeutic
agents TMZ and/or VPA differs in glioblastoma cell lines
In general, GBM is a radio- and chemo-resistant tumor.
However, in consistence with its great heterogeneity, a
wide range of radiosensitivity has been demonstrated
with in vitro clonogenic and in vivo assays based on
xenogeneic mouse models [45]. Williams et al. analyzed
the clonogenic potential of 39 tumor cell lines and found
the three human glioblastoma cell lines T98G, U251MG,
and U87MG as the most resistant cell lines in a dose
range 2-10Gy [46,47]. The MGMT status of the glio-
blastoma cells is involved in responsiveness to TMZ. We
detected a high steady state mRNA and MGMT protein
expression levels in U251MG and T98G, but not in
U87MG glioblastoma cells (not shown).
Our data show that T98G and U251MG, which express
MGMT and contain mutant p53, are more resistant to ra-
diation than U87MG with no MGMT expression and p53
WT (Figure 1). Approximately 29% of T98G, 25% of
U251MG and 7% of U87MG survived after a radiation
dose of 6Gy. At a dosage above 6Gy, the cell line U251MG
showed also an enhanced sensitivity to radiation compared
to T98G (Figure 1A, B).
A promising approach for the treatment of GBM pa-
tients are radiosensitizers. Therefore, the radiosensitizing
effect of the alkylating chemotherapeutic agent TMZ and
the anti-epileptic drug and histone deacetylase inhibitor
VPA alone or in combinations were tested. In T98G
tumor cells, neither TMZ nor VPA alone or the combin-
ation did reduce the colony formation. Further, only VPA
or the combination of VPA with TMZ exerted slight radio-
sensitizing effects (Figure 1A). In contrast, colony forma-
tion of the cell line U251MG was suppressed when TMZ
or VPA were combined alone with RT (≥4Gy). A further
significant reduction of the colony numbers was achieved
when TMZ plus VPA were combined together with RT
(Figure 1B). Unlike T98G and U251MG glioblastoma cells,
the p53 WT and MGMT negative cell line U87MG was
highly sensitive to TMZ. TMZ reduced the capability to
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Figure 1 Colony formation of glioblastoma cells after treatment with RT and/or CT with TMZ and/or VPA. T98G (A), U251MG (B), or
U87MG (C) tumor cells were treated with TMZ (20 μM) and/or VPA (0.5 mM) alone, or in combination with RT. The dose-dependent clonogenic
potential was determined after 2 weeks of incubation. The colony number (100%) of untreated cells was set as 1, and the reduction of the colony
number due to treatment was calculated accordingly. Data from one experiment representative of at least two independent experiments is
shown (n = 3). Mean values (±SD) are displayed. Gy, Gray; RT, radiotherapy; CT, chemotherapy; w/o, untreated control; TMZ, temozolomide; VPA,
valproic acid; # P < 0.05, ## P < 0.01, ### P < 0.001 (TMZ ± RT against w/o ± RT), *P < 0.05, **P < 0.01, ***P < 0.001 (TMZ/VPA ± RT against
w/o ± RT), + P < 0.05, ++ P < 0.01, +++ P < 0.001 (VPA ± RT against w/o ± RT).
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(Figure 1C). The combination with RT (≥ 2Gy) resulted in
the complete loss of colony formation. VPA also sensitized
U87MG to radiation (≥ 4Gy). Since TMZ alone was
already a very effective radiosensitizer, the combination of
TMZ and VPA could not further potentiate the growth in-
hibitory effect exerted by TMZ.Fractionated RT induces apoptosis and necrosis in
glioblastoma cells
As outlined above, TMZ in combination with VPA sensi-
tizes the human glioblastoma cell lines T98G, U251MG
and U87MG to radiation, monitored by a significant
reduction of colony formation. Since this assay gives no
information about cell death induction and immunological
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AnxA5-FITC/PI assay. Although during the last years sev-
eral data about tumor cell death induction by radiation
and/or chemotherapeutic agents were published, the focus
was mainly set on high single doses of X-rays [48] or high
concentrations of CT [3,10,19,49]. To get hints how clinic-















































































































Figure 2 Forms of glioblastoma cell death after fractionated RT and/o
(C) tumor cells were treated with TMZ (20 μM) and/or VPA (0.5 mM) alone
hours after the last treatment, cells were stained with AnxA5-FITC/PI and cell d
primary, or secondary necrotic tumor cells are displayed. Pooled results of fou
triplicates. Mean values (±SD) are displayed. Gy, Gray; RT, radiotherapy; CT, che
acid; 1°, primary; 2°, secondary; ## P < 0.01, ### P < 0.001 (against w/o), *P < 0.
VPA + TMZ± RT), + P < 0.05, +++ P < 0.001 (VPA ± RT against VPA + TMZ ± RTglioblastoma cells, we analyzed the cell death forms of the
glioblastoma cell lines after fractionated irradiation with
5x2Gy in combination with clinically relevant concentra-
tion of TMZ and/or VPA in 2D culture systems.
Figure 2A and B display cell death forms of T98G and
U251MG glioblastoma cells two days after the last treat-


















































r CT with TMZ and/or VPA. T98G (A), U251MG (B), or U87MG
, or in combination with 5 daily radiation doses of 2Gy. Forty-eight
eath was analyzed by flow cytometry. The percentages of apoptotic,
r independent experiments are shown, each performed at least in
motherapy; w/o, untreated control; TMZ, temozolomide; VPA, valproic
05, ***P < 0.001 (against RT), §§ P < 0.01, §§§ P < 0.001 (TMZ ± RT against
).
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sulted in a significantly increased number of both apop-
totic and necrotic cells. A radiosensitizing effect regarding
apoptosis and necrosis induction by TMZ, VPA or TMZ
plus VPA was not observed (Figure 2A and B). This was
also true when higher concentrations of TMZ (200 μM)
or a daily dose of TMZ (20 μM)/VPA (0.5 mM) were
administered (data not shown). A slight, but significant
increase of apoptosis and necrosis was seen in non-
irradiated T98G glioblastoma cells when they were treated
with a combination of TMZ and VPA (Figure 2A).
In p53 WT and MGMT negative U87MG glioblastoma
cells, CT and fractionated RT alone and combinatory
treatments induce predominantly necrotic tumor cell
death
Treatment of U87MG cells with TMZ and/or VPA with-
out irradiation resulted in significantly increased amounts
of apoptotic and necrotic tumor cells. Necrosis dominated
over apoptosis and VPA was a stronger inducer of nec-
rotic cell death compared to TMZ (Figure 2C). Fraction-
ated RT alone again significantly increased glioblastoma
tumor cell death. Combinations with CT further signifi-
cantly increased apoptosis and, in the presence of VPA,
also necrosis of U87MG glioblastoma cells (Figure 2C). As
observed for T98G and U251MG cells, fractionated RT
induced a mixture of apoptotic and necrotic cell death.
However, in U87MG cells with WT p53, combinations
with VPA predominantly induced necrotic tumor cell
death and VPA further potentiated the effects of TMZ or
TMZ+ RT (Figure 2C). Of note is that the observed ne-
crosis is not RIPK1-dependent necroptosis, since glioblast-
oma cell death induced by RT and/or CT was inhibitable
by zVAD-fmk, but not by necrostatin-1 (not shown).
Fractionated RT induces a G2-cell cycle arrest in
glioblastoma cells
Ionizing radiation and TMZ are known to induce an ar-
rest of tumor cells in the G2 phase of the cell cycle. In
this phase the cells are highly susceptible to further
irradiation.
Around one third of T98G or U251MG cells arrested in
the G2 phase of the cell cycle as early as 4 h after exposure
to fractionated RT. The G2-arrest sustained for at least
48 hours after the last fractionation dose (Figure 3A and
B). The importance of applying fractionated schemes re-
sembling the clinical situation for preclinical evaluations is
indicated by the fact that irradiation of T98G with a single
dose of 10Gy did not induce a G2 cell cycle block when
monitored from 4 up to 72 h after the irradiation (data
not shown). In contrast, in U251MG cells a significant
G2-cell cycle block occurred after a single irradiation with
10Gy. However, it occurred later (after 24 h) and declined
faster (data not shown).Temozolomide induces a G2 cell cycle arrest only in
U87MG, but not in T98G and U251MG cells
TMZ did not induce an accumulation of the p53 mutant
glioblastoma cell lines T98G and U251MG in the G2-
phase of the cell cycle (Figure 3A and B). In contrast, in
p53 WT U87MG cells, not only fractionated RT induced
a significant G2-block, but also a comparable level was
achieved by treatment with TMZ alone or in combin-
ation with VPA (Figure 3C). Combinations of fraction-
ated RT with TMZ led to a massive arrest of the tumor
cells in the G2-phase of the cell cycle; around 65% two
days after the last irradiation. Treatment of U87MG with
TMZ was further associated with the appearance of hy-
perploid cells with a DNA content greater than 4n (data
not shown). In U87MG cells, VPA did also slightly, but
significantly increase the percentage of the tumor cells
in the G2-phase of the cell cycle.
TMZ, VPA, TMZ plus VPA and combinations with frac-
tionated RT further increased the amount of the subG1-
DNA content of the cells, indicating that late apoptosis/
secondary necrosis is induced in U87MG cells (Figures 2C
and 3C).
Increased release of the danger signal Hsp70 after
fractionated RT of glioblastoma cell lines
Nowadays it is well accepted that the immune system
contributes to the elimination of tumor cells. However,
glioblastoma tumors evolved multiple mechanisms to
evade immunological surveillance. Some chemothera-
peutics and/or ionizing radiation are known to stimulate
an anti-tumor immune response in several cancers by
the induction of immunogenic cell death forms (sum-
marised in [50,51]). Since the immunogenic potential of
tumor cells can be determined by their release of danger
signals, we analyzed the concentration of HMGB1 and
of Hsp70 in supernatants of glioblastoma cell cultures
treated with fractionated RT and/or CT. Five daily doses
of 2Gy significantly increased the amount of extracellu-
lar Hsp70 in all three investigated glioblastoma cell lines
(Figure 4A). Combined treatment with CT did not fur-
ther increase the secretion of Hsp70. In contrast, the
amount of extracellular HMGB1 was not significantly
altered after exposure of the glioblastoma cell line
U87MG to fractionated RT and/or CT. However, a
slight, but significant increased amount of extracellular
HMGB1 was observed in T98G and U251MG tumor
cells after fractionated RT, especially in combinations
with VPA (Figure 4B).
Discussion
Radio-resistance [52] and innate or acquired resistance
to CT [53-55] are among the reasons for poor control
and treatment responses of GBM. Consequently, an ur-








































































































































Figure 3 (See legend on next page.)
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Figure 3 Glioblastoma cells in the G2 cell cycle phase and with subG1-DNA-content after fractionated RT and/or CT. T98G (A), U251MG
(B), or U87MG (C) tumor cells were treated with TMZ (20 μM) and/or VPA (0.5 mM) alone, or in combination with 5 daily radiation doses of 2Gy.
Forty-eight hours after the last treatment, cells were harvested. For determination of the DNA content, cells was stained with PI and analyzed by
flow cytometry. The percentage of cells in the G2-phase of the cell cycle and that of the subG1-population with degraded DNA are displayed.
Pooled results of four independent experiments are shown, each performed at least in triplicates. Mean values (±SD) are displayed. Gy, Gray; RT,
radiotherapy; CT, chemotherapy; w/o, untreated control; TMZ, temozolomide; VPA, valproic acid; # P < 0.05, ## P < 0.01, ### P < 0.001 (against w/o),
**P < 0.01, ***P < 0.001 (against RT), §§§ P < 0.001 (TMZ ± RT against VPA + TMZ ± RT), + P < 0.05, +++ P < 0.001 (VPA ± RT against VPA + TMZ ± RT).
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http://www.ro-journal.com/content/9/1/89combinations to improve the outcome of patients with
GBM. Recent clinical data have shown that the median
survival can be improved after an additional treatment
of patients with VPA [13,56] and immune therapeutic
approaches are promising [57].
The tumor suppressor gene p53 is involved in cellular
radiosensitivity and mutated in more than 50% of gli-
omas [20,58]. As expected, the p53 mutant gliomblas-
toma cell lines T98G and U251MG showed an increased
clonogenic survival after RT compared to the p53 WT
cell line U87MG (Figure 1A-C). Only in the p53 WT












































Figure 4 Hsp70 and HMGB1 release of the glioblastoma cell lines T98
treated with TMZ (20 μM) and/or VPA (0.5 mM) alone, or in combination with
supernatants were analyzed for the amount of extracellular Hsp70 (A) or HMG
two independent experiments, each performed in duplicates. Mean value
w/o, untreated control; TMZ, temozolomide; VPA, valproic acid, HMGB1: D
70; # P < 0.05, ## P < 0.01, ### P < 0.001 (against w/o).highly radiosensitizing effect (Figure 1C) of TMZ was ob-
served. After combined treatment of RT and TMZ, colony
formation in U251MG was only slightly impaired and in
T98G completely unaffected (Figure 1A, B).
Besides the tumor suppressor p53, the MGMT status
of cells is involved in responsiveness to TMZ [59].
Yoshino et al. found no MGMT mRNA and protein ex-
pression in U87MG and U251MG, but in T98G. The
IC50 values of MGMT negative cell lines U87MG and
U251MG were 23.0 μM and 22.5 μM, respectively, and
441.6 μM for MGMT positive T98G cells [60]. There-



























G, U251MG, and U87MG after RT and/or CT. The tumor cells were
5 daily radiation doses of 2Gy. Forty-eight hours after the last treatment,
B1 (B) by ELISA. The data show one representative experiment of at least
s (±SD) are displayed. Gy, Gray; RT, radiotherapy; CT, chemotherapy;
NA-binding protein high-mobility group B1; Hsp70, heat shock protein
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et al., we (data not shown) and others [3,61] obtained
much higher IC50 values for TMZ in U87MG, U251MG
(<200 μM), and T98G (>500 μM). TMZ concentrations
that are reached in patients were found to be only suffi-
cient to completely eliminate glioblastoma stem cells
in vitro from MGMT negative but not from MGMT
positive tumors [62]. Hermisson et al. described that
U251MG cells have no significant MGMT activity and
are therefore rather sensitive to TMZ [63]. However, we
found high steady state mRNA and MGMT protein ex-
pression levels not only in T98G, but also U251MG glio-
blastoma cells. The latter were rather resistant to TMZ
with regard to the clonogenicity (Figure 1). Therefore,
we assume that MGMT expression and its accompanied
TMZ resistance can be acquired during cell culture due
to epigenetic alterations and the focus should be more
set on p53 mutation status for experiments dealing with
radiosensitizing effects on glioblastoma cell lines. Even
in the clinic the MGMT promoter methylation status
used as a prognostic and predictive marker for GBM
should be handled with care [64].
From cell culture experiments, it has been reported
that VPA sensitizes human glioma cells to γ-radiation
and TMZ [19,61]. Data from colorectal cancer cells sug-
gest a p53 dependency of radiosensitization by VPA [65].
Our results show that, depending of radiation dose, VPA
is capable of enhancing the radiosensitivity of both p53
mutant and p53 WT glioblastoma cell lines as analyzed
by the reduction of their clonogenic potential (Figure 1).
Further, this HDAC inhibitor potentiated the effect of
TMZ in MGMT expressing and p53 mutated T98G and
U251MG. HDAC inhibitors are known as activators of
methylated genes [66]. VPA alone had no cytotoxic ef-
fect in our experiments when administered at a concen-
tration of 0.5 mM. The IC50 values of VPA determined
by us (data not shown) and others exceeded 5 mM [61].
However, because of its radiosensitizing properties
(Figure 1) in addition to its antiepileptic effect, VPA
should be considered to be applied in combination with
standard therapy of GBM. VPA further induced a
slightly increased release of HMGB1 in T98G and
U251MG glioblastoma cells when combined with frac-
tionated RT (Figure 4B).
If DNA is damaged by radiation or cytotoxic agents,
cells stop their cell cycle and start to repair. Non
reparable damage results in the initiation of cell death.
Fractionated RT induced a G2-arrest in p53 WT and
mutated glioblastoma cell lines (Figure 3A-C). The sen-
sitivity to TMZ was associated with an intact p53 and
inactive MGMT status, because only in the p53 WT and
MGMT negative cell line U87MG a G2-block occurred
with an even higher intensity then seen after fractionated
RT (Figure 3C). A combination of both (RT + TMZ)resulted in around 20% more cells in the G2-phase than
single TMZ or RT. The experiments further showed that
fractionated RT induced a mixture of apoptosis and ne-
crosis in all three glioblastoma cell lines (Figure 2A-C).
But only in U87MG cells TMZ, VPA and TMZ + VPA
alone or their combinations with fractionated RT induced
significantly more cell death compared to non-treated or
RT-treated controls.
For long-lasting success of multimodal cancer therapies,
an induction of systemic anti-tumor immunity, besides
the local tumor control by stopping the proliferation of
malignant tumor cells, is more and more considered to be
of importance [50]. Anti-tumor immunity strongly de-
pends on the induction of immunogenic forms of tumor
cell death [67,68]. Only very few preclinical data exist on
how fractionated irradiation used in clinical routine im-
pacts on cell death forms of tumor cells. Therefore, we
treated GBM cell lines with 5 daily radiation doses of 2Gy
alone or in combination with a single administration of
TMZ (20 μM) and/or VPA (0.5 mM). Fractionated RT
was capable of inducing necrotic glioblastoma cells
(Figure 2), as it was also the case for TMZ in p53 WTcells
(Figure 2C). Others demonstrated that TMZ administra-
tion results in apoptosis [10,69,70] or autophagy [3] in gli-
oma cells. TMZ-induced apoptosis is stimulated by p53
and requires an un-methylated MGMT promotor. We
also found a slight increase of apoptosis after TMZ treat-
ment, but only in U87MG cells. Roos et al. showed that
apoptosis signals through Fas/CD95/Apo-1 receptor in
p53 WT and through the mitochondrial pathway p53 mu-
tated glioma cells, respectively [69]. In western blot ana-
lyses we did not observe significant changes in protein
levels of pro- and anti-apoptotic proteins involved in the
mitochondrial pathway, including Bax, caspase 3 and 7,
PUMA, Bcl-2 or XIAP. However, glioblastoma cell death
induced by RT and/or CT was inhibitable by the pan-
caspase inhibitor zVAD-fmk, but not by necrostatin-1 (not
shown). We therefore conclude that the detected necrosis
by AnxA5-FITC/PI staining results from apoptotic cells
that have lost their membrane integrity during the execu-
tion phase of apoptosis. Further, TMZ induced p21 in
U87MG cells (data not shown).
We describe for the first time that necrotic glioblastoma
cells occur after TMZ treatment at clinically relevant con-
centrations (20 μM) (Figure 3C). Since fractionated RT
alone or in combination with TMZ are capable of indu-
cing bigger amounts of dying cells, the phagocyte system
might be overcharged, resulting in necrotic glioblastoma
cells not only in vitro, but also in vivo [24,35]. Jakubowicz-
Gil and colleagues also observed a shift of apoptotic to
necrotic cell death in T98G after prolonged TMZ incuba-
tion (≥48 h) and higher concentrations (>100 μM) [70].
The prolonged incubation time (≥5d) with the low TMZ
(20 μM) concentrations in our experimental settings
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http://www.ro-journal.com/content/9/1/89might be the reason for the early appearance of necrotic
glioblastoma cells in p53 WT U87MG, but not in p53 mu-
tated T98G or U251MG. Further, apoptosis and necrosis
induction in U251MG cells was observed after combined
treatment with heat (42°C) and the Hsp90 inhibitor NVP-
HSP990 [71].
The presence of necrosis and the resulting release of
danger signals is accomplished by an immunogenic tumor
microenvironment [24,72], which is required for an ame-
liorated therapeutic outcome in anticancer therapy. Im-
mune stimulatory necrosis was also predominantly
observed after treatment with VPA (0.5 mM) and its com-
binations (TMZ, RT, TMZ+RT) in U87MG (Figure 2C).
Further the parallel treatment of U87MG with VPA, TMZ,
RT and/or RT + TMZ increased both necrotic and apop-
totic cell death compared to controls. Figure 5 summa-
rizes how an immune stimulatory microenvironment may
be induced by fractionated RT +/- TMZ/VPA in p53 WT
and p53 mutated glioblastoma tumor cells.
Van Nifterik et al. published that VPA does not
antagonize the cytotoxic effect of TMZ and is therefore
not contraindicated during radiochemotherapy of patients
with GBM [19]. It was important for us to use clinical
relevant concentrations of CT in our in vitro settings. The
reached VPA levels in the brain differ between publica-
















Figure 5 Hypothesis how especially fractionated RT may induce imm
positive glioblastoma cell lines T98G and U251MG, fractionated RT is the m
and necrosis concomitant with the release of the danger signal Hsp70. Esp
concentrations of extracellular amounts of the danger signal HMGB1. In p5
is one main stimulus for G2 cell cycle arrest and reduction of clonogenic “s
cells concomitant with Hsp70 after fractionated RT of all examined glioblas
potential. TMZ, temozolomide; VPA, valproic acid, HMGB1: DNA-binding pro
mutated; WT: wild type.20-100 μg/ml in epileptic patients, whereby brain levels
only reach about 7-28% of the total levels [15]. Li et al.
state that VPA concentrations in the cerebrospinal fluid
are nearly the same as the free concentration in plasma by
a half-life time of 9 to 20 hours [17]. In our study, we de-
cided to add VPA to the culture before TMZ and the first
RT treatment, because it has been reported that VPA im-
proves the accessibility of DNA to alkylating agents and
RT by loosen up the chromatin structure through histone
acetylation [73]. Van Nifterik et al. only found a radiosen-
sitizing effect of VPA when added before irradiation [19].
In contrast, Camphausen et al. and Chinnaiyan et al.
showed an enhanced radiation response when VPA was
added before or after RT. Importantly, VPA can sensitize
glioma cells for up to 24 hours after radiation [74]. As de-
scribed above, our study shows that VPA predominantly
results in necrotic tumor cells in U87MG, but does not
affect p53 mutated T98G or U251MG (Figure 2). The re-
sults of Fu and colleagues indicate that VPA induces au-
tophagy [18], while others report about an apoptotic
tumor cell death after VPA [75]. Chen et al. further dem-
onstrated that the synergistic effect of VPA and TMZ for
the induction of apoptosis is independent of an intact p53
and suggest a clinical potential for a combined therapy in
p53 mutated gliomas. However, our data reveal a more
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http://www.ro-journal.com/content/9/1/89promising sensitizer for TMZ and fractionated RT and cell
death inductor in p53 WT and MGMT negative cells
(U87MG), no significant effects were seen in p53 mutated
and MGMT positive T98G. Therefore, it might be useful
to test more sensitive HDAC inhibitors in combination
with TMZ and RT for p53 mutated glioblastoma cells in
the future.
In addition to analyzing the influence of fractionated
RT alone or in combination with TMZ and/or VPA on
the cell cycle progression (Figure 3) and cell death forms
(Figure 2) of glioblastoma cells, we were further inter-
ested in the release of the danger signals HMGB1 and
Hsp70 after the treatments. While the amount of extra-
cellular HMGB1 was only slightly increased in T98G
and U251MG cells especially after combination of RT
with VPA, fractionated RT in general resulted in in-
creased extracellular concentrations of Hsp70 in all ex-
amined glioblastoma cell lines (Figure 4). Extracellularly
present Hsp70 is known to be an immune modulator,
which fosters the stimulation and activation of immune
cells, including DC and natural killer cells [76,77]. The
treatment with five daily doses of 2Gy increased the
amount of extracellular Hsp70 significantly in T98G,
U251MG, and U87MG. However, TMZ and VPA alone
or a combination did not significantly increase extracel-
lular Hsp70 levels, except after exposure of U87MG cells
to VPA only (Figure 4). Radiation has been found to
modulate cytosolic and surface Hsp70 levels of specific-
ally tumor cells [78]. However, the release could not be
induced by a single radiation dose, as shown by Schild-
kopf et al. for human colorectal tumor cell lines. Only
the combination with hyperthermia (HT) increased the
amount of extracellular Hsp70 as well as necrotic cell
death [79,80]. Therefore, we assume that predominantly
repeated exposure to RT leads to early appearance of
necrotic glioblastoma cells and to an increased release of
Hsp70. Both could be relevant for the induction of anti-
tumor immune responses [81]. In future experiments we
will analyze how the Hsp70 containing supernatants of
glioblastoma cells modulate maturation and activation of
DC as well as the consecutive T cell priming. It has be-
come evident that DC-based immune therapies are
promising for GBM. Pilot studies and phase I and II tri-
als have been performed indicating that vaccination with
DC improves immune functions and results in longer
survival of patients with malignant gliomas. The authors
conclude that DC-vaccination in combination with RT
and TMZ in patients with GBM is safe, feasible, and
capable of inducing tumor-specific immune responses
[57,82-86]. In our first analyses of biopsies of GBM pa-
tients we detected a higher expression level of Hsp70 in
relapses compared to the primary tumor (unpublished
data). This might indicate that especially in the relapse
situation DC-based immune therapies will work well.Conclusions
Our in vitro data suggest that fractionated RT is the
main stimulus for cell death induction and Hsp70 re-
lease of especially p53 mutated and MGMT negative
glioblastoma cells. Since Hsp70 is capable of activating
DC, future preclinical and clinical work has to identify
whether high extracellular concentrations of Hsp70 after
fractionated RT generates a tumor microenvironment of
GBM that favors additional immunotherapy.
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